Investor Presentaiton

95 Investor presentation Full year 2022 Ziltivekimab phase 2b RESCUE trial was successfully completed In the RESCUE trial, zilti QM showed reduction in hsCRP at all dose levels placebo I ziltivekimab 15 mg Iziltivekimab 7.5 mg Iziltivikemab 30 mg % change¹ 0% 2 . 12 weeks of treatment Zilti QM showed reductions in inflammation biomarkers³ End of treatment -5% -3% . -20% Zilti QM appeared to have a safe and well-tolerated profile -40% -60% -80% -77% * -88% -92% -100% * -79% * -91% -93% . • Novo NordiskⓇ Addressing the residual risk of CVD for more than 5 million patients with ASCVD, CKD, and inflammation4 The phase 3 cardiovascular outcomes trial was initiated in Q3 2021 1 Primary endpoint was the median percent change in hsCRP, * Indicates statistical significance, p < .0001 2 End of treatment is defined as the average of values at week 23 and week 24 3 Inflammation biomarkers include: Fibrinogen, serum amyloid A, haptoglobin and NTproBNP 4 Inflammation is defined as c-reactive protein levels greater than 2 Zilti: Ziltivekimab; QM: Once-montly; hsCRP: High-sensitivity C-reactive protein; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease

View entire presentation